Información del artículo
El Texto completo está disponible en PDF
Bibliogrífia
[1.]
J.H. Hoofnagle, K.D. Mullen, D.B. Jones, V. Rusti, A.D. Di Bisceglie, M. Peters, et al.
Treatment of chronic non-A non-B hepatitis recombinant human alpha-interpheron: a preliminary report.
N Engl J Med, 315 (1986), pp. 1575-1578
[2.]
R. Carithers, S. Emerson.
Therapy of hepatitis C: meta-analysis of interferon alfa 2b trials.
Hepatology, 26 (1997), pp. 83-88
[3.]
W. Lee.
Therapy of hepatitis C: interferon alfa 2a trials.
Hepatology, 26 (1997), pp. 89-95
[4.]
E. Jaeckel, M. Cornberg, H. Wedemeyer, T. Santantonio, J. Mayer, M. Zankel, et al.
Treatment of acute hepatitis C with interferon alfa 2 b.
N Engl J Med, 345 (2001), pp. 1452-1457
[5.]
O. Reichartdt, J. Anderson, R. Schvarcz, O. Weiland.
Ribavirin treatment for chronic hepatitis C.
Lancet, 337 (1991), pp. 1058-1061
[6.]
A. Di Bisceglie, S.H. Conjevaram, M.W. Fried, R. Sallie, Y. Park, C. Yurdaydin, et al.
Ribavirin as therapy for chronic hepatitis C. A randomised, double blind, controlled trial.
Ann Intern Med, 123 (1995), pp. 897-903
[7.]
M.Y. Lai, J.H. Kao, P.M. Yang, J. Wang, P. Chen, K. Chan, et al.
Long term efficacy of ribavirin plus interferon in the treatment of chronic hepatitis C.
Gastroenterology, 111 (1996), pp. 1307-1312
[8.]
O. Reichardt, G. Norkrans, A. Fryden, J. Braconier, A. Sonneborg, O. Weiland, et al.
Randomised, double blind, placebo controlled trial of interferon alpha 2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.
Lancet, 351 (1998), pp. 83-87
[9.]
T. Poynard, P. Marcellin, S.S. Lee, C. Niederau, G.S. Minuk, G. Ideo, et al.
Randomised trial of interferon alfa 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.
Lancet, 352 (1998), pp. 1426-1432
[10.]
J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shifman, W.M. Lee, V.K. Rutsgi, et al.
Interferon alfa 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.
N Engl J Med, 339 (1998), pp. 1485-1492
[11.]
J.G. McHutchison, T. Poynard.
Combination therapy with interferon plus ribavirin as initial treatment for chronic hepatitis C.
Semin Liver Dis, 19 (1999), pp. 57-66
[12.]
O. Weiland.
Treatment of naïve patients with chronic hepatitis C.
J Hepatology, 31 (1999), pp. 168-173
[13.]
T. Poynard, J. McHutchison, Z. Goodman, M.H. Ling.
Albrecht J for the ALGOVIR Project Group. Is an «a la carte» combination interferon alfa 2b plus ribavirin regimenpossible for the first line treatment in patients with chronic hepatitis C?.
Hepatology, 31 (2000), pp. 211-218
[14.]
P. Marcellin, J. Heathcote, H. Bismuth, V. Desmet, J. Guardia, A. Lok, et al.
À la carte interferon for hepatitis C?.
Hepatology, 32 (2000), pp. 678-679
[15.]
J. McHutchison, T. Poynard, J. Harvey, J. Garaud, J. Albrecht.
The effect of dose reduction on sustained response in patients with chronic hepatitis C receiving interferon alfa 2b in combination with ribavirin.
Hepatology, 32 (2000), pp. 223A
[16.]
J.R. Azanza.
Interferones pegilados: revisión preliminar de sus características farmacocinéticas.
Rev Clin Esp, 201 (2001), pp. 205-212
[17.]
M.W. Modi, J.S. Fulton, D.K. Buckmann, T. Wright, D. Moore, et al.
Clearance of pegylated (40kDA) interferon alfa 2a is primarily hepatic.
Hepatology, 32 (2000), pp. 317A
[18.]
P. Martin, S. Mitra, K. Farrington, N.E. Martin, M.W. Modi.
Pegylated (40 kD) interferon alfa 2a (PEGASYS) is unaffected by renal impairment.
Hepatology, 32 (2000), pp. 370A
[19.]
N.E. Martin, M.W. Modi, K.R. Reddy.
Characterization of pegylated (40 kD) interferon alfa 2a in the elderly.
Hepatology, 32 (2000), pp. 348A
[20.]
P. Glue, J.W. Fang, R. Rouzier Panis.
Pegylated interferon alfa 2b: pharmacocinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
Clin Pharmacol Ther, 68 (2000), pp. 556-557
[21.]
P. Glue, R. Rouzier Panis, C. Raffanel, R. Sabo, S.K. Gupta, M. Salfi, et al.
A dose ranging study of pegylated interferon alfa 2b and ribavirin in chronic hepatitis C.
Hepatology, 32 (2000), pp. 647-653
[22.]
S. Zeuzem, V. Feinman, J. Rasenack, J. Heatchote, M.Y. Lai, E. Gane, et al.
Peginterferon alfa 2a in patients with chronic hepatitis C.
N Engl J Med, 343 (2000), pp. 1666-1672
[23.]
J. Heathcothe, M.L. Shiffman, W. Graham, W.G.E. Cooksley, G. Dusheiko, S.S. Lee, et al.
Peginterferon alfa 2a in patients with chronic hepatitis C and cirrhosis.
N Engl J Med, 343 (2000), pp. 1673-1680
[24.]
C. Trepo, K. Lindsay, C. Niederau, M. Shiffman, S. Gordon, J. Hoefs, et al.
Pegylated interferon alfa 2b (PEG-INTROM) monotherapy is superior to interferon alfa 2b (INTROM A) for the treatment of chronic hepatitis C.
J Hepatol, 32 (2000), pp. 29
[25.]
M. Manns, J. McHutchison, S. Gordon, V. Rustgi, M. Shiffman, R. Reindollar, et al.
Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Lancet, 358 (2001), pp. 958-965
[26.]
M. Fried, M. Shiffman, R. Reddy, C. Smith, G. Marinos, F. Goncales, et al.
Pegylated (40 kDa) Interferon alfa-2a (PEGASYS) in combination with ribavirin: efficacy and safety results from a phase III ramdomized, actively controlled multicenter study.
Gastroenterology, 120 (2001), pp. 55A
[27.]
P. Ferenci, M. Shiffman, M. Fried, M. Sulkowski, D. Haeussinger, J.P. Zarski, et al.
Early prediction of response to 40 KDA peginterferón alfa-2a (Pegasys) plus ribavirin in patients with chronic hepatitis C.
Hepatology, 34 (2001), pp. 351A
[28.]
S. Hadziyannis, H. Cheinquer, T. Morgan, M. Diago, D. Jensen, H. Sette, et al.
Prospective evaluation of early virological response associated with 40 kDa peginterferon alfa-2a (Pegasys) plus ribavirin therapy from a phase III. ramdomized, double blind study axamining the effects of treatment duration and ribavirin dosing.
Hepatology, 34 (2001), pp. 328A
[29.]
T. Hassanein, G. Cooksley, M. Sulkowski, C. Smith, G. Marinos, M. Lai, et al.
Treatment with 40 kDa peginterferon alfa-2a (Pegasys) in combination with ribavirin significantly enhaces quality of life compared with interferon alfa 2b plus ribavirin.
Hepatology, 34 (2001), pp. 243A
[30.]
A. Talal, K. Weisz, T. Hau, S. Kreiswirth, D. Dieterich.
A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alfa.
Am J Gastroenterl, 96 (2001), pp. 2802-2804
[31.]
M. Diago, D. Suárez, L. García Villarreal, A. Castro, A. Domínguez, M. Pardo, et al.
Multicenter ramdomized study comparing initial daily induction with high dose lymphoblastoid interferon versus standar interferon treatment for chronic hepatitis C.
J Med Virol, 64 (2001), pp. 460-465
[32.]
P. Ferenci, H. Brunner, K. Nachbaur, C. Datz, M. Gchwantler, H. Hofer, et al.
Combination of interferon induction therapy and ribavirin in chronic hepatitis C.
Hepatology, 34 (2001), pp. 1006-1011
[33.]
J. Fang, E. Hespenheid, C. Driscoll.
Amantadine HCL treatment of chronic hepatitis C.
Hepatology, 26 (1997), pp. 217A
[34.]
S. Zeuzem, G. Teuberg, U. Naumann, T. Berg, J. Raedle, S. Hartmann, et al.
Randomizd, double blind, placebo controlled trial of interferon alfa 2a with and without amantadine as initial treatment for chronic hepatitis C.
Hepatology, 32 (2000), pp. 835-841
[35.]
M. Tabone, C. Laudi, B. Delmastro, A. Biglino, M. Andreoni, F. Chieppa, et al.
Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients.
J Hepatol, 35 (2001), pp. 517-521
[36.]
S. Caronia, M. Bassendine, R. Barry, P. Mills, N. Naumov, R. Fox, et al.
Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study.
J Hepatol, 35 (2001), pp. 512-516
[37.]
A. Mangia, N. Minerva, M. Annese, G. Leandro, M. Villani, R. Santoro, et al.
A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C.
Hepatology, 33 (2001), pp. 989-993
[38.]
S. Brillanti, F. Levantesi, L. Masi, M. Foli, L. Bolondi.
Triple antiviral therapy as a new option for patients with interferon non responsive chronic hepatitis C.
Hepatology, 3 (2000), pp. 630-634
[39.]
A. Di Bisceglie, D. Bernstein, V. Rustgi, N. Gitlin, L. Jeffers, D. Simonds, et al.
Pegylated (40 kDa) interferon alfa 2a (Pegasys) in new combination therapies: a report of o randomized, multicener efficacy and safety study.
J Hepatol, 3 (2001), pp. 143S
[40.]
M. Tong, L. Balart, J. McHutchison, R. Co, A. Conrad.
Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison.
Hepatology, 26 (1997), pp. 1640-1645
[41.]
J. Mc Hutchison, J. Shad, S. Gordon, T. Morgan, M. Ling, J. Garaud, et al.
Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCBV RNA results during therapy.
J Vit Hepatitis, 8 (2001), pp. 414-420
[42.]
T. Fukutomi, M. Nakamuta, M. Fukutomi, M. Iwao, H. Watanabe, K. Hiroshige, et al.
Decline of hepatitis C virus load in serum during the first 24 h after administration of interferon beta as a predictor of the efficacy of therapy.
J Hepatol, 34 (2001), pp. 100-107
[43.]
T. Poynard, J. McHutchison, M. Manns, C. Trepo, K. Lindsay, Z. Goodman, et al.
Impact of pegylated interferon alfa 2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.
Hepatology, 34 (2001), pp. 244A
[44.]
Y. Lurie, R. Pakula, S. Malnick, M. Beer-Gabel, K. Gelshen.
Efficacy and safety of the combination histamine dihydrochloride and interferon alfa 2b in a phase II trial in naïve patients with chronic hepatitis C.
Hepatology, 34 (2001), pp. 350A
[45.]
S. Zeuzem, U. Hopf, V. Carreño, M. Diago, M. Shiffman, S. Grüne, et al.
A phase I/II study of recombinant human interleukin 12 in patients with chronic hepatitis C.
Hepatology, 29 (1999), pp. 1280-1287
[46.]
P. Pockros, J. McHutchison, C. O’Brien, M. Tong, C. Smith, V. Rustgi, et al.
A phase II randomized, double blind, placebo controlled, multicenter study of recombinant interleukin 12 for the treatment of chronic hepatitis C infection in patients non responsive to previous treatment with interferon alfa with or without ribavirin.
Hepatology, 34 (2001), pp. 350A
[47.]
K. Sherman, M. Sjogren, R. Creager.
Combination therapy with thymosin alpha 1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double blind trial.
Hepatology, 27 (1998), pp. 1128-1135
[48.]
D. Macejak, K. Jensen, S. Jamison.
Inhibition of HCV RNA dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes.
Hepatology, 31 (2000), pp. 769-776
[49.]
J. McHutchison, P. Pockros, L. Nyberg, T. Kwoh, F. Dorr.
A dose escalation study of ISIS 14803 an antisense inhibitor of HCV. in chronic hepatitis C patients.
Hepatology, 34 (2001), pp. 350A
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
